Imatinib Eg (Imatinib)

Imatinib is a tyrosine kinase inhibitor used in hematologic and solid‑tumor malignancies that depend on BCR‑ABL, c‑KIT, or PDGFR signaling.

• Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and achieves cytogenetic and molecular remission.
• Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): improves remission rates and survival when combined with chemotherapy.
• Gastrointestinal stromal tumor (GIST): inhibits tumor growth and prolongs progression‑free survival in patients with KIT or PDGFRA mutations.

• Imatinib selectively inhibits the tyrosine kinases BCR‑ABL, c‑KIT, and PDGFR by binding to their ATP‑binding sites. This blocks downstream signaling pathways such as RAS‑RAF‑MEK‑ERK and PI3K‑AKT, which are essential for malignant cell proliferation, survival, and angiogenesis, thereby inducing apoptosis and disease control.

Adverse reactions may vary in frequency and severity.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Edema: peripheral swelling, often in the ankles.
• Muscle cramps: intermittent skeletal muscle discomfort.
• Fatigue: generalized tiredness affecting daily activities.

Serious or Rare Side Effects

• Severe neutropenia: marked reduction in white blood cells, increasing infection risk.
• Hepatotoxicity: elevated liver enzymes or hepatitis.
• Cardiac failure: reduced cardiac output, especially in patients with pre‑existing heart disease.
• Pulmonary hypertension: elevated pressure in lung arteries, potentially life‑threatening.

Careful monitoring and patient education are essential when using Imatinib.

• Monitor blood counts: perform regular CBC to detect cytopenias.
• Assess liver function: check hepatic enzymes before and during therapy.
• Evaluate cardiac status: baseline and periodic ECG or echocardiogram for patients with cardiac history.
• Avoid in known hypersensitivity: discontinue if severe allergic reaction occurs.
• Store at ambient temperature: keep in the original container, protect from moisture and heat.

Imatinib can interact with several drug classes, requiring dose adjustments or avoidance.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase Imatinib exposure.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic levels.
• Warfarin: concurrent use can enhance anticoagulant effect and raise INR.
• QT‑prolonging agents (e.g., quinidine, sotalol): increase risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inhibitors (e.g., fluconazole): may modestly raise Imatinib concentrations.
• Proton pump inhibitors: may slightly decrease absorption.
• Diuretics: can exacerbate electrolyte disturbances when combined with Imatinib‑related fluid retention.
• NSAIDs: may increase bleeding tendency, especially with concomitant thrombocytopenia.